rs12998806
|
|
G |
0.710 |
GeneticVariation |
GWASCAT |
In addition, we confirmed SNP rs10069690 was the best indicator for ER-negative breast cancer at 5p15.33 (OR = 1.30; P = 2.4 × 10 − 10) and identified rs12998806 as the best indicator for ER-positive breast cancer at 2q35 (OR = 1.34; P = 2.2 × 10 − 8) for women of African ancestry.
|
28171663 |
2016 |
rs12998806
|
|
|
0.710 |
GeneticVariation |
BEFREE |
In addition, we confirmed SNP rs10069690 was the best indicator for ER-negative breast cancer at 5p15.33 (OR = 1.30; P = 2.4 × 10 − 10) and identified rs12998806 as the best indicator for ER-positive breast cancer at 2q35 (OR = 1.34; P = 2.2 × 10 − 8) for women of African ancestry.
|
28171663 |
2016 |
rs11251942
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
rs12938141
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
rs140538758
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
rs4717568
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
rs587150
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
rs62235635
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
rs6938753
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
rs7082321
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
rs73370840
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
rs79116769
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study of germline variants and breast cancer-specific mortality.
|
30787463 |
2019 |
rs12586722
|
|
A |
0.700 |
GeneticVariation |
GWASCAT |
SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
|
28429243 |
2017 |
rs2981579
|
|
T |
0.700 |
GeneticVariation |
GWASCAT |
Genome-Wide Testing of Exonic Variants and Breast Cancer Risk in the California Teachers Study.
|
28864454 |
2017 |
rs10941679
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation.
|
27640304 |
2016 |
rs700518
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Because AI use results in severe estrogen deficiency that may lead to changes in body composition, the aim of this study was to determine the effect of the rs700518 polymorphism in the CYP19A1 gene on the changes in body composition among postmenopausal women who were treated with AIs for ER+ breast cancer.
|
26049585 |
2015 |
rs865686
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We recently identified a novel susceptibility variant, rs865686, for estrogen-receptor positive breast cancer at 9q31.2.
|
25652398 |
2015 |
rs10941679
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In addition, we find both rs4415084 and rs10941679 conferred significantly greater risks of ER-positive breast cancer than of ER-negative tumors.
|
24039999 |
2013 |
rs700518
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
|
23643682 |
2013 |
rs865686
|
|
|
0.020 |
GeneticVariation |
BEFREE |
9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium.
|
22859399 |
2012 |
rs17822931
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our data showed that a significant association between rs17822931 and the risk of breast cancer, especially ER-positive breast cancer, in Japanese women.
|
30883634 |
2019 |
rs192876988
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In follow-up studies of the 10 identified variants, the GK2 region SNP, rs192876988, showed an inverse association with EOC in European ancestry women (p = 0.002), increased risk of ER positive breast cancer in African ancestry women (p = 0.027) and decreased expression of GK2 in HGSOC tissue from African ancestry women (p = 0.004).
|
31469419 |
2019 |
rs4442975
|
|
|
0.010 |
GeneticVariation |
BEFREE |
SNP rs4442975 was associated with a greater reduction of risk of ER-positive breast cancer [odds ratio (OR)int = 0.85 (0.78-0.93), Pint = 2.8 x 10-4] and overall breast cancer [ORint = 0.85 (0.78-0.92), Pint = 7.4 x 10-5) in current users of estrogen-progesterone therapy compared with non-users.
|
31605532 |
2019 |
rs13689
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The C allele of <i>CDH1</i>:rs13689 (odds ratio [OR], 2.121; <i>p</i>=0.033) was found to be associated with ER-positive breast cancer.
|
29963112 |
2018 |
rs992531
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified a novel locus (rs992531 at 8p21.2) associated with reduced survival among the patients with ER-positive breast cancer (<i>P =</i> 3.77 × 10<sup>-8</sup>).
|
29423119 |
2018 |